Scinai regains Nasdaq minimum bid price compliance

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced it received written notification from Nasdaq Listing Qualifications confirming the company has regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).

Nasdaq notified Scinai on March 12, 2026, that the company's American Depositary Shares had failed to maintain a minimum bid price of $1.00 over the prior 30 consecutive business days.

In a compliance letter dated September 18, 2026, Nasdaq stated that for 19 consecutive business days from August 21, 2026, through September 17, 2026, the closing bid price of Scinai's ADSs was at $1.00 per share or greater, satisfying the listing rule requirement.

"Receiving Nasdaq's confirmation closes an important compliance matter for Scinai," said Amir Reichman, Chief Executive Officer of Scinai. "We appreciate Nasdaq Staff's review and constructive engagement throughout the process. With this matter resolved, our focus remains on commercial execution at Scinai Biopharma Services and disciplined advancement of our NanoAb programs."

Scinai is a biopharmaceutical company based in Jerusalem that operates a contract development and manufacturing organization through its subsidiary, Scinai Biopharma Services Ltd., with facilities in Jerusalem and Yavne, Israel.

You May Also Be Interested In

• Fortitude Mining ups DCG credit facility to $50M, adds ZEC funding
• Granite Point plans reverse stock split, reviews strategic options
• Capital Clean Energy Carriers elects new board member, loses veteran director